AstronauTx has secured funding from The Michael J. Fox Foundation and Parkinson's UK for two preclinical programmes testing whether pharmacologically enhanced slow-wave sleep can slow Parkinson's pathology. One study examines ligand-gated ion channel modulation in prodromal synucleinopathy; the other, led at University College London, measures whether increased slow-wave activity accelerates glymphatic clearance of alpha-synuclein in a mouse model. The lead programme is being prepared for clinical development in 2027.
Key Points
- Funding targets sleep-based disease modification in preclinical Parkinson's models
- Slow-wave sleep tested as driver of glymphatic alpha-synuclein clearance
- Lead programme positioned for clinical development in 2027
Longevity Analysis
Deep sleep functions as the brain's principal waste-clearance window, and the accumulation of misfolded alpha-synuclein reflects a failure of that nightly removal process rather than an isolated pathological event. Treating sleep architecture as a modifiable variable — not merely a symptom of neurodegeneration — reframes disturbed sleep in the prodromal period as an early, actionable signal rather than an inevitability. The broader implication extends past Parkinson's: anything that degrades slow-wave activity, from alcohol and late-evening light exposure to untreated sleep apnoea, plausibly compromises the same clearance pathway across decades.
Original published by Longevity.Technology.